The ROE as of December 2024 (TTM) for Gain Therapeutics, Inc. (GANX) is -203.91%

According to Gain Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -203.91%. This represents a change of 300.90% compared to the average of -50.86% of the last 4 quarters.

Gain Therapeutics, Inc. (GANX) Historical ROE (quarterly & annually)

How has GANX ROE performed in the past?

The mean historical ROE of Gain Therapeutics, Inc. over the last ten years is 39.34%. The current -203.91% ROE has changed -618.28% with respect to the historical average. Over the past ten years (40 quarters), GANX's ROE was at its highest in in the March 2019 quarter at 487.59%. The ROE was at its lowest in in the June 2023 quarter at -69.31%.

Gain Therapeutics, Inc. (GANX) ROE by Quarter and Year

Discovering the peaks and valleys of Gain Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gain Therapeutics, Inc. (GANX) Average ROE

How has GANX ROE performed in the past?

The current ROE of Gain Therapeutics, Inc. (GANX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Gain Therapeutics, Inc. (GANX) ROE vs. Peers

How is GANX’s ROE compared to its peers?

Gain Therapeutics, Inc.’s ROE is greater than BioVie Inc. (-188.95%), greater than IN8bio, Inc. (-197.15%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), greater than Cue Biopharma, Inc. (-156.38%), greater than TFF Pharmaceuticals, Inc. (-310.17%), greater than aTyr Pharma, Inc. (-56.83%), greater than Lantern Pharma Inc. (-56.90%), less than Eliem Therapeutics, Inc. (0%), less than Inhibrx Biosciences, Inc. (0%), less than Merrimack Pharmaceuticals, Inc. (1.45%), greater than Celcuity Inc. (-35.28%), greater than Enliven Therapeutics, Inc. (-62.66%), greater than Molecular Partners AG (-29.46%), greater than MediciNova, Inc. (-39.16%), greater than Anebulo Pharmaceuticals, Inc. (-20.70%), greater than Champions Oncology, Inc. (-184.40%), less than Cyteir Therapeutics, Inc. (66.22%), greater than null (-9.44%),

Build a custom stock screener for Gain Therapeutics, Inc. (GANX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gain Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gain Therapeutics, Inc. (GANX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gain Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.